BioInvent International AB (publ) (FRA:BIX0)

Market Cap	134.59M -16.7%
Revenue (ttm)	20.93M +406.9%
Net Income	-30.76M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	159
Open	2.025
Previous Close	2.120
Day's Range	2.025 - 2.025
52-Week Range	1.946 - 3.680
Beta	n/a
RSI	42.58
Earnings Date	Mar 31, 2026

About FRA:BIX0

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 109
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BIX0

Financial Performance

In 2025, FRA:BIX0's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.

Financial numbers in SEK